ARS Pharmaceuticals, Inc. (SPRY) research
ARS Pharmaceuticals, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.07
- As of
ARS Pharmaceuticals, Inc. (SPRY): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.
As of . Source: SEC EDGAR filings for SPRY. Method and limitations.
Share the SPRY intelligence card
See the full SPRY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SPRY on one page. Preview it with sample data, then open it live with a free account.
Preview the SPRY dossierActive signals for SPRY
- highCONSENSUS_SELL
3 tracked funds reduced SPRY this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 98% of SPRY (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 60% of SPRY (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 79% of SPRY (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 70% of SPRY (2026Q2)
FREE, NO ACCOUNT
Every signal on SPRY, as it fires
You are seeing 5 of 14 signals recorded on SPRY since 2026-05-30.
The five above landed across 2 days. The other 9 were recorded on 4 other days. 8 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SPRY (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 82835W108 · 2026Q2 | $19.2M | 0.01% | , |
| Third Point LLCCUSIP 82835W108 · 2026Q2 | $8M | 0.17% | , |
| CITADEL ADVISORS LLCCUSIP 82835W108 · 2026Q2 | $4.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 82835W108 · 2026Q2 | $420K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SPRY
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
SPRY against its peers
SPRY's operating margin of -212.9% ranks in the 42nd percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | SPRY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 84.3M USD | 42.6M USD | 81 | 12 |
| Operating margin | -212.9% | -142.7% | 42 | 12 |
| Net margin | -203.3% | -141.4% | 42 | 12 |
| Return on equity | -149.9% | -69.4% | 18 | 19 |
Peers (21): KYTX, MYGN, EDIT, RLMD, ZURA, GALT, AGEN, TTRX, RZLT, CCCC, INDP, PRTA, TECX, DMAC, IRD, ENTA, ARCT, ENTX, ASMB, FENC, OBIO. Left out: SCTX (no annual filing), EIKN (no annual filing), PRTC (period gap), AGMB (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (SPRY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SPRY signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SPRYand get the insider, 13F, options, and confluence read in one view.